Back to News
Market Impact: 0.15
Clearmind Gains Japan Patent Coverage For 3-MMC And PEA Combination
Source: Nasdaq
Patents & Intellectual PropertyHealthcare & Biotech
Clearmind Medicine announced publication in Japan of a patent application covering novel compositions and methods for treating dyskinesia, a neurological movement disorder involving involuntary movements. The announcement does not specify whether the patent has been granted or provide clinical or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CMND0.45
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- William Blair downgrades Alignment Healthcare stock rating on cost pressures